GlassScriptPhysician profile
Robin Matsukawa
NPI 1568668325
$1,051.22
in general payments reported to CMS, 2019-2025
14 companies · $428 in 2025
The $428 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2020: $33.17 · 2023: $114 · 2024: $357 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $767 · Education: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $767.26 |
| Education | $132.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $319.24 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $186.90 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $138.97 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $61.57 | 2025 | Trelegy Ellipta |
| Amgen INC. | $58.75 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.96 | 2019-2025 | Jardiance |
| Exact Sciences Corporation | $42.85 | 2025 | The Cologuard Plus Collection Kit |
| Pfizer INC. | $37.05 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $31.74 | 2023 | Dupixent |
| Gilead Sciences, INC. | $29.93 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.52 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.26 | 2023 | Entyvio |
| Janssen Pharmaceuticals, INC | $23.20 | 2019 | |
| Esperion Therapeutics, INC. | $20.28 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Matsukawa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.